Estudo randomizado | Tratamento com mepolizumabe interrompido vs. continuado por longo prazo na asma eosinofílica grave.
29 Ago, 2022 | 13:44h
Comentário no Twitter
This randomised study demonstrates increased exacerbation risk and a decrease in asthma control in patients with severe eosinophilic asthma who stop mepolizumab treatment after long-term use, when compared with those who continue treatment. https://t.co/HYCH0TsU9E pic.twitter.com/rW6hmHgJlj
— ERS publications (@ERSpublications) January 6, 2022